FDA Brief

Warning letters Drugs

FDA warning letter to

Diora Kimya Sanayi ve Ticaret Limited Sirketi

High riskIssued Oct 17, 2024Posted Oct 22, 2024Center for Drug Evaluation and Research (CDER)

FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.

What happened

FDA inspected the drug manufacturing facility from May 27 to 31, 2024 and found failures in current good manufacturing practice (CGMP), including missing component identity testing, missing finished-product assay testing before release, and incomplete process and cleaning validation. FDA also found Personal CARE Antibacterial Soap (NDC 72133-049) was not properly listed and was inactivated as of January 31, 2024, and it placed the firm on Import Alert 66-40 on October 16, 2024.

What FDA found

  1. The firm did not test each component lot to verify identity and relied on suppliers' certificates of analysis without establishing the reliability of the suppliers' test results at appropriate intervals.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm released drug batches without appropriate finished-product testing, including assay testing for identity and strength of active ingredients, and transcribed supplier component results onto finished-product certificates.

    21 CFR 211.165(a)
  3. The firm had not completed process validation or cleaning validation for non-dedicated equipment and lacked documentation that its equipment was qualified and suitable for its intended use.

    21 CFR 211.100(a)
  4. Personal CARE Antibacterial Soap (NDC 72133-049) was not certified as required and was inactivated as of January 31, 2024, so it was not included in an FDA drug listing while in commercial distribution.

    section 510(j) of the FD&C Act; 21 CFR Part 207
  5. FDA said some products may be cosmetics and may be adulterated if prepared, packed, or held under insanitary conditions.

    section 601(c) of the FD&C Act

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. If it cannot finish within that time, it must explain the delay and give a completion schedule.

Who should pay attention

  • brands that buy OTC topical drugs from this contract manufacturer
  • U.S. distributors and importers of Personal CARE Antibacterial Soap
  • companies using glycerin or other high-risk drug components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk